Potential Protection of Pre-Existent Antibodies to Human Coronavirus 229E on COVID-19 Severity

The causes of the broad spectrum of severity in COVID-19 are unknown. A protecting impact by humoral immunity from earlier infections by viruses of the SARS-CoV-2 household may clarify a light type of this illness. This examine aimed to deal with whether or not the presence of antibodies in opposition to human seasonal coronaviruses (HCoVs) may forestall extreme manifestations of COVID-19.
A cross-sectional examine was carried out in 165 members. The presence of pre-existent antibodies in opposition to the seasonal HCoV-OC43, HCoV-HKU1, HCoV-229E, and HCoV-NL63 have been detected. From all the seasonal HCoVs studied, it was solely discovered that being seropositive to HCoV-229E introduced an affiliation (p = 0.012) with creating delicate medical signs of COVID-19 or being asymptomatic.
Multinomial regression evaluation confirmed that being seropositive to HCoV-229E is related to delicate or reasonable medical signs for COVID-19. Statistical evaluation additionally confirmed that being feminine is related to being asymptomatic for SARS-CoV-2 an infection or creating delicate COVID-19.
A subgroup evaluation taking solely seropositive to HCoV-229E revealed that females usually tend to develop asymptomatic SARS-CoV-2 an infection (OR = 27.242, 95% CI 2.092-354.706, p = 0.012). Our outcomes recommend that earlier infections by HCoV-229E may forestall extra critical medical manifestations of COVID-19, however these should not the one variables that affect this occasion.

The comparative efficacy and security of anti-CD20 monoclonal antibodies for relapsing-remitting a number of sclerosis: A community meta-analysis

With the latest profitable concentrating on of B lymphocytes in sufferers with a number of sclerosis (MS), therapy with anti-CD20 monoclonal antibodies (mAbs) might characterize a promising managemental strategy, significantly for these with relapsing/remitting MS (RRMS).
A community meta-analysis was carried out based mostly on a complete search in Embase, PubMed, and the Cochrane Library to evaluate the comparative efficacy and security of at present obtainable anti-CD20 monoclonal antibodies (mAbs), together with rituximab, ocrelizumab, and ofatumumab, versus a standard comparator (interferon beta-1a [INFβ-1a]) in RRMS sufferers recruited in randomized medical trials (RCTs).
In a frequentist community meta-analytical mannequin, annualized relapse charges (ARRs) and security outcomes have been expressed as threat ratios (RRs), whereas relapse-free occasions have been expressed as odds ratios (ORs). Remedy rating was carried out utilizing P-scores. The knowledge of proof was appraised utilizing the GRADE strategy.
5 publications reported the outcomes of seven RCTs (3938 sufferers, 67.09% females). In comparison with INFβ-1a, ocrelizumab lowered the chance of ARR (RR = 0.56, 95% CI, 0.50-0.64), critical adversarial occasions (RR = 0.17, 95% CI, 0.09-0.30), and therapy discontinuation as a consequence of adversarial occasions (SAEs, RR = 0.60, 95% CI, 0.39-0.93), and it was related to larger odds of no relapses (OR = 2.47, 95% CI, 2.00-3.05).
Ocrelizumab ranked finest amongst all different remedies by way of lowering ARR and SAEs. The standard of proof was low for ocrelizumab, low to reasonable for rituximab, and excessive for ofatumumab. Additional large-sized, well-designed RCTs are wanted to corroborate the efficacy and security of ocrelizumab and different anti-CD20 mAbs in RRMS.

Fc Receptor Variants and Illness: A Essential Issue to Contemplate within the Antibody Therapeutics in Clinic

The fragment crystallizable (Fc) area of antibodies is answerable for their protecting perform and long-lasting serum half-life by way of Fc-mediated effector perform, transcytosis, and recycling by its interplay with Fc receptors (FcRs) expressed on varied immune leukocytes, epithelial, and endothelial cells. Due to this fact, the Fc-FcRs interplay is a management level of each endogenous and therapeutic antibody perform.
There are a variety of reported genetic variants of FcRs, which embrace polymorphisms in (i) extracellular area of FcRs, which change their affinities to Fc area of antibodies; (ii) each cytoplasmic and intracellular area, which alters the extent of sign transduction; and (iii) the promoter area of the FcRs gene, which impacts the expression degree of FcRs, thus being related to the pathogenesis of illness indications.
On this assessment, we firstly describe the correlation between the genetic variants of FcRs and immunological problems by particular person variations within the extent of FcRs-mediated laws. Secondly, we focus on the affect of the genetic variants of FcRs on the susceptibility to infectious ailments or most cancers within the perspective of FcRs-induced effector capabilities. General, we concluded that the genetic variants of FcRs are one of many key components within the design of antibody therapeutics as a consequence of their number of medical outcomes amongst people.
 Potential Protection of Pre-Existent Antibodies to Human Coronavirus 229E on COVID-19 Severity

SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies Could Ameliorate COVID-19 Issues in APECED Sufferers

Sufferers with the monogenic immune dysregulatory syndrome autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), which is brought on by loss-of-function mutations within the autoimmune regulator (AIRE) gene, uniformly carry neutralizing autoantibodies directed in opposition to type-I interferons (IFNs) and lots of develop autoimmune pneumonitis, each of which place them at excessive threat for life-threatening COVID-19 pneumonia.
Bamlanivimab and etesevimab are monoclonal antibodies (mAbs) that focus on the SARS-CoV-2 spike protein and block entry of SARS-CoV-2 in host cells. Using bamlanivimab and etesevimab early throughout an infection was related to lowered COVID-19-associated hospitalization and dying in sufferers at excessive threat for progressing to extreme illness, which led the US Meals and Drug Administration to subject an emergency use authorization for his or her administration in non-hypoxemic, non-hospitalized high-risk sufferers.
Nevertheless, the protection and efficacy of those mAbs has not been evaluated in APECED sufferers. We enrolled two siblings with APECED on an IRB-approved protocol  and admitted them prophylactically on the NIH Medical Heart for analysis of mild-to-moderate COVID-19. We assessed the protection and medical results of early therapy with bamlanivimab and etesevimab.
The administration of bamlanivimab and etesevimab was effectively tolerated and was related to amelioration of COVID-19 signs and prevention of invasive ventilatory help, admission to the intensive care, and dying in each sufferers with out affecting the manufacturing of antibodies to the nucleocapsid protein of SARS-CoV-2.
If given early in the midst of COVID-19 an infection, bamlanivimab and etesevimab could also be useful in APECED and different high-risk sufferers with neutralizing autoantibodies directed in opposition to type-I IFNs.
 Potential Protection of Pre-Existent Antibodies to Human Coronavirus 229E on COVID-19 Severity

Case Report: Full Response of Main Large Hepatocellular Carcinoma to Anti-Programmed Demise Ligand-1 Antibody Following Development on Anti-Programmed Demise-1 Antibody

Hepatocellular carcinoma (HCC) is an aggressive liver tumor that happens as a consequence of persistent liver illness, and it has a excessive mortality charge and restricted therapy choices. Immune checkpoint inhibitors have been efficiently launched and utilized in most cancers remedy, amongst which inhibitors of programmed dying ligand-1 (PD-L1) and its receptor programmed death-1 (PD-1) are generally administered for HCC as mixture remedy, together with mixed anti-angiogenic and immunotherapy mixture remedy.
 Potential Protection of Pre-Existent Antibodies to Human Coronavirus 229E on COVID-19 Severity
We report a case of a main large HCC affected person with portal hepatic vein tumor thrombus who had a great response to atezolizumab together with bevacizumab, following development of illness on mixed immunotherapy with pembrolizumab and lenvatinib.

Recombinant Human α-1-Acid Glycoprotein 2/AGP2/ORM2 (C-6His)

CD54-50ug 50ug
EUR 363.6
Description: Lyophilized from a 0.2 μm filtered solution of 20mM Tris, 150mM NaCl, pH 8.0.

CD54 antibody (biotin)

61R-1516 100 ug
EUR 379.2
Description: Mouse monoclonal CD54 antibody (biotin)

ICAM1/CD54 Antibody

35344-100ul 100ul
EUR 468

CD54 Antibody (Biotin)

abx139537-01mg 0.1 mg
EUR 510

CD54 Antibody (FITC)

abx139538-100tests 100 tests
EUR 510

CD54 (pT512) Antibody

20-abx009840
  • EUR 376.80
  • EUR 560.40
  • EUR 243.60
  • 100 ul
  • 200 ul
  • 30 ul

CD54 Blocking Peptide

20-abx062764
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

ICAM-1/CD54

PR27037 2 ug
EUR 229.2

Anti-CD54 antibody

STJ16100956 100 tests
EUR 738

Anti-CD54 antibody

STJ16101113 100 µg
EUR 424.8

Anti-CD54 antibody

STJ190018 200 µl
EUR 236.4
Description: Unconjugated Mouse monoclonal to CD54 (AS1A33)

ICAM1 Antibody / CD54

RQ5121 100ul
EUR 419

ICAM1 Antibody / CD54

V7851-100UG 100 ug
EUR 499
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. ICAM-1 may also be related to progression and metastasis of tumors.

ICAM1 Antibody / CD54

V7851-20UG 20 ug
EUR 219
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. ICAM-1 may also be related to progression and metastasis of tumors.

ICAM1 Antibody / CD54

V7851SAF-100UG 100 ug
EUR 499
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. ICAM-1 may also be related to progression and metastasis of tumors.

ICAM1 Antibody / CD54

V2604-100UG 100 ug
EUR 499
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1) (Workshop IV). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. W-CAM-1 mAb blocks aggregation of cell lines mediated by the ICAM-1 and blocks homotypic binding of purified populations of activated T- and B-lymphocytes and also aggregation of mixed T- and B-cell blasts. It inhibits T-cell adhesion to normal human endothelial cells. Activation induced by cell-cell contact (mixed lymphocyte reaction, T-cell mediated B-cell activation) is significantly inhibited. This mAb blocks elements of both effector arms of immune system (cytotoxic cell function and Ig production).

ICAM1 Antibody / CD54

V2604-20UG 20 ug
EUR 219
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1) (Workshop IV). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. W-CAM-1 mAb blocks aggregation of cell lines mediated by the ICAM-1 and blocks homotypic binding of purified populations of activated T- and B-lymphocytes and also aggregation of mixed T- and B-cell blasts. It inhibits T-cell adhesion to normal human endothelial cells. Activation induced by cell-cell contact (mixed lymphocyte reaction, T-cell mediated B-cell activation) is significantly inhibited. This mAb blocks elements of both effector arms of immune system (cytotoxic cell function and Ig production).

ICAM1 Antibody / CD54

V2604IHC-7ML 7 ml
EUR 499
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1) (Workshop IV). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. W-CAM-1 mAb blocks aggregation of cell lines mediated by the ICAM-1 and blocks homotypic binding of purified populations of activated T- and B-lymphocytes and also aggregation of mixed T- and B-cell blasts. It inhibits T-cell adhesion to normal human endothelial cells. Activation induced by cell-cell contact (mixed lymphocyte reaction, T-cell mediated B-cell activation) is significantly inhibited. This mAb blocks elements of both effector arms of immune system (cytotoxic cell function and Ig production).

ICAM1 Antibody / CD54

V2604SAF-100UG 100 ug
EUR 499
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1) (Workshop IV). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. W-CAM-1 mAb blocks aggregation of cell lines mediated by the ICAM-1 and blocks homotypic binding of purified populations of activated T- and B-lymphocytes and also aggregation of mixed T- and B-cell blasts. It inhibits T-cell adhesion to normal human endothelial cells. Activation induced by cell-cell contact (mixed lymphocyte reaction, T-cell mediated B-cell activation) is significantly inhibited. This mAb blocks elements of both effector arms of immune system (cytotoxic cell function and Ig production).

ICAM1 Antibody / CD54

V2605-100UG 100 ug
EUR 499
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM1 also binds to CD43 and to Plasmodium falciparum infected RBCs and may also be related to progression and metastasis of tumors.

ICAM1 Antibody / CD54

V2605-20UG 20 ug
EUR 219
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM1 also binds to CD43 and to Plasmodium falciparum infected RBCs and may also be related to progression and metastasis of tumors.

ICAM1 Antibody / CD54

V2605SAF-100UG 100 ug
EUR 499
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM1 also binds to CD43 and to Plasmodium falciparum infected RBCs and may also be related to progression and metastasis of tumors.

ICAM1 Antibody / CD54

V9194-100UG 100ug
EUR 499
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. ICAM-1 may also be related to progression and metastasis of tumors.

ICAM1 Antibody / CD54

V9194-20UG 20ug
EUR 219
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. ICAM-1 may also be related to progression and metastasis of tumors.

ICAM1 Antibody / CD54

V9194SAF-100UG 100ug
EUR 499
Description: Recognizes an 85-115kDa protein (variation with cell type), identified as intercellular adhesion molecule (ICAM-1). It has 7 potential N-linked glycosylation sites. ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes. ICAM-1 mediates cell adhesion by binding to integrins CD11a/CD18 (leukocyte adhesion molecule, LFA-1) and to CD11b/CD18 (Mac-1). This interaction enhances antigen-specific T-cell activation. ICAM-1 also binds to CD43 and to Plasmodium falciparum infected RBCs. ICAM-1 may also be related to progression and metastasis of tumors.

ICAM1 Antibody / CD54

V9197-100UG 100ug
EUR 499
Description: ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes.

ICAM1 Antibody / CD54

V9197-20UG 20ug
EUR 219
Description: ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes.

ICAM1 Antibody / CD54

V9197SAF-100UG 100ug
EUR 499
Description: ICAM-1 is a single chain glycoprotein of Ig supergene family, present on unstimulated endothelial cells (EC) and on a variety of other cell types including activated fibroblasts, EC, macrophages, and lymphocytes.

sICAM-1/CD54 ELISA Kit| Rat CD54 ELISA Kit

EF018233 96 Tests
EUR 826.8

Anti-Hu CD54 PE

1P-228-T025 25 tests
EUR 168

Anti-Hu CD54 PE

1P-228-T100 100 tests
EUR 288

Anti-Hu CD54 PE

1P-429-T025 25 tests
EUR 168

Anti-Hu CD54 PE

1P-429-T100 100 tests
EUR 288

Anti-Ms CD54 Purified

11-625-C025 0.025 mg
EUR 91.2

Anti-Ms CD54 Purified

11-625-C100 0.1 mg
EUR 135.6

Anti-Hu CD54 Purified

11-228-C025 0.025 mg
EUR 118.8

Anti-Hu CD54 Purified

11-228-C100 0.1 mg
EUR 189.6

Anti-Hu CD54 Purified

11-229-C025 0.025 mg
EUR 118.8

Anti-Hu CD54 Purified

11-229-C100 0.1 mg
EUR 189.6

Anti-Hu CD54 APC

1A-429-T025 25 tests
EUR 168

Anti-Hu CD54 APC

1A-429-T100 100 tests
EUR 288

Anti-Hu CD54 Biotin

1B-429-C025 0.025 mg
EUR 146.4

Anti-Hu CD54 Biotin

1B-429-C100 0.1 mg
EUR 244.8

Anti-Hu CD54 FITC

1F-429-T025 25 tests
EUR 146.4

Anti-Hu CD54 FITC

1F-429-T100 100 tests
EUR 244.8

Anti-Ms CD54 FITC

1F-625-C100 0.1 mg
EUR 212.4

CD54 (pY512) Blocking Peptide

20-abx062763
  • EUR 376.80
  • EUR 610.80
  • 1 mg
  • 5 mg

Anti-Hu CD54 PerCP

PC-429-T025 25 tests
EUR 168

Anti-Hu CD54 PerCP

PC-429-T100 100 tests
EUR 288

ICAM-1 / CD54 Recombinant Protein

11-541 0.1 mg
EUR 714.3
Description: Inter-Cellular Adhesion Molecule 1 (ICAM-1) is also known as Cluster of Differentiation 54 (CD54), is a member of the immunoglobulin superfamily, and is a cell surface glycoprotein which is typically expressed in low concentrations on endothelial cells and cells of the immune system. The protein encoded by this gene is a type of intercellular adhesion molecule continuously present in low concentrations in the membranes of leukocytes and endothelial cells. Upon cytokine stimulation, the concentrations greatly increase. ICAM-1 can be induced by interleukin-1 (IL-1) and tumor necrosis factor alpha (TNFα) and is expressed by the vascular endothelium, macrophages, and lymphocytes. ICAM-1 is a ligand for LFA-1 (integrin), a receptor found on leukocytes. When activated, leukocytes bind to endothelial cells via ICAM-1/LFA-1 and then transmigrate into tissues. ICAM-1 has been implicated in subarachnoid hemorrhage (SAH). Levels of ICAM-1 are shown to be significantly elevated in patients with SAH over control subjects in many studies. ICAM-1 expressed by respiratory epithelial cells is also the binding site for rhinovirus, the causative agent of most common colds.

CD54(ICAM-1) Monoclonal Antibody

27176-100ul 100ul
EUR 302.4

CD54(ICAM-1) Monoclonal Antibody

27176-50ul 50ul
EUR 224.4

CD54 (ICAM-1) Antibody (Biotin)

abx021458-02mg 0.2 mg
EUR 886.8

CD54 (ICAM-1) Antibody (PE)

abx022366-100ug 100 ug
EUR 644.4

CD54 (ICAM-1) Antibody (Biotin)

abx022368-05mg 0.5 mg
EUR 861.6

Anti-Hu CD54 Alexa Fluor700

A7-429-T025 25 tests
EUR 184.8

Anti-Hu CD54 Alexa Fluor700

A7-429-T100 100 tests
EUR 322.8

Monoclonal ICAM-1 / CD54 Antibody

AMM01772G 0.05mg
EUR 580.8
Description: A Monoclonal antibody against Human ICAM-1 / CD54. The antibodies are raised in Mouse. This antibody is applicable in IHC-P, IP, IHC-Fr, Flo

Monoclonal CD54(ICAM-1) Antibody

AMM03141G 0.1ml
EUR 580.8
Description: A Monoclonal antibody against Human CD54(ICAM-1). The antibodies are raised in Mouse. This antibody is applicable in WB

Monoclonal CD54(ICAM-1) Antibody

AMM03142G 0.1ml
EUR 580.8
Description: A Monoclonal antibody against Human CD54(ICAM-1). The antibodies are raised in Mouse. This antibody is applicable in WB, ICC

Anti-CD54/ICAM-1 antibody

STJ16100016 100 µg
EUR 724.8

Anti-CD54/ICAM-1 antibody

STJ16100017 50 µg
EUR 622.8

Anti-CD54/ICAM-1 antibody

STJ16100067 100 µg
EUR 487.2

Anti-CD54/ICAM-1 antibody

STJ16100068 100 µg
EUR 487.2

Anti-CD54 (ICAM-1) antibody

STJ99079 200 µl
EUR 236.4
Description: Mouse monoclonal to CD54 (ICAM-1).

Anti-CD54 (ICAM-1) antibody

STJ99080 200 µl
EUR 236.4
Description: Mouse monoclonal to CD54 (ICAM-1).

Mouse Anti Human Cd54 Monoclonal Antibody

CABT-46474MH 0.2 mg
EUR 889.2

Mouse Anti Human Cd54 Monoclonal Antibody

CABT-49499MH 0.2 mg
EUR 982.8

Rabbit Anti Human Cd54 Polyclonal Antibody

CPBT-65044RH 0.1 mg
EUR 1057.2

CD54 / ICAM-1 (F4-31C2) Antibody

BNCA1249-250 250uL
EUR 459.6
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), APC conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNCAP1249-100 100uL
EUR 238.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNCAP1249-500 500uL
EUR 652.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC611249-100 100uL
EUR 238.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF660R conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC611249-500 500uL
EUR 652.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF660R conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNUM1249-50 50uL
EUR 474
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), 1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNCP1249-250 250uL
EUR 459.6
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), PerCP conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNCR1249-250 250uL
EUR 459.6
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), RPE conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNUB1249-100 100uL
EUR 250.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), Concentration: 0.2mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNUB1249-500 500uL
EUR 549.6
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), Concentration: 0.2mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC431249-100 100uL
EUR 238.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF543 conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC431249-500 500uL
EUR 652.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF543 conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC051249-100 100uL
EUR 238.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF405M conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC051249-500 500uL
EUR 652.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF405M conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC401249-100 100uL
EUR 238.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF640R conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC401249-500 500uL
EUR 652.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF640R conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC811249-100 100uL
EUR 238.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF680R conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC811249-500 500uL
EUR 652.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF680R conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC881249-100 100uL
EUR 238.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF488A conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC881249-500 500uL
EUR 652.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF488A conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC801249-100 100uL
EUR 238.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF680 conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC801249-500 500uL
EUR 652.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF680 conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNCH1249-100 100uL
EUR 238.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNCH1249-500 500uL
EUR 652.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC041249-100 100uL
EUR 238.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF405S conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC041249-500 500uL
EUR 652.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF405S conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC681249-100 100uL
EUR 238.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF568 conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC681249-500 500uL
EUR 652.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF568 conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC701249-100 100uL
EUR 238.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF770 conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC701249-500 500uL
EUR 652.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF770 conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC941249-100 100uL
EUR 238.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF594 conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC941249-500 500uL
EUR 652.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF594 conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC551249-100 100uL
EUR 238.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF555 conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC551249-500 500uL
EUR 652.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF555 conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNCB1249-100 100uL
EUR 238.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), Biotin conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNCB1249-500 500uL
EUR 652.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), Biotin conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC471249-100 100uL
EUR 238.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF647 conjugate, Concentration: 0.1mg/mL

CD54 / ICAM-1 (F4-31C2) Antibody

BNC471249-500 500uL
EUR 652.8
Description: Primary antibody against CD54 / ICAM-1 ( F4-31C2), CF647 conjugate, Concentration: 0.1mg/mL

Mouse ICAM-1/CD54 ELISA Kit

EMI0332 96Tests
EUR 625.2

Human ICAM-1/CD54 ELISA Kit

EHI0332 96Tests
EUR 625.2

Porcine ICAM-1/CD54 ELISA Kit

EPI0332 96Tests
EUR 625.2

Rat ICAM-1/CD54 ELISA Kit

ERI0332 96Tests
EUR 625.2

Rabbit ICAM-1/CD54 ELISA Kit

ERTI0332 96Tests
EUR 625.2

Human CellExp? ICAM1 /CD54, human recombinant

7486-100
EUR 861.6

Human CellExp? ICAM1 /CD54, human recombinant

7486-20
EUR 320.4

anti-CD54 IgG2b-k monoclonal antibody

068-A-01mg 0,1 mg
EUR 321
Description: anti-CD54 IgG2b-k monoclonal antibody

anti-CD54 IgG2b-k monoclonal antibody

068-A-1000ug 1000 ug
EUR 1539
Description: anti-CD54 IgG2b-k monoclonal antibody

Anti-Hu CD54 Purified Azide Free

10-429-C025 0.025 mg
EUR 118.8

Anti-Hu CD54 Purified Azide Free

10-429-C100 0.1 mg
EUR 189.6

Anti-Ms CD54 Purified Low Endotoxin

12-625-C100 0.1 mg
EUR 178.8

Intercellular Adhesion Molecule 1 (CD54) Antibody

20-abx134369
  • EUR 427.20
  • EUR 678.00
  • EUR 360.00
  • 100 ul
  • 200 ul
  • 50 ul

Intercellular Adhesion Molecule 1 (CD54) Antibody

abx139530-01mg 0.1 mg
EUR 427.2

Intercellular Adhesion Molecule 1 (CD54) Antibody

abx139531-01mg 0.1 mg
EUR 427.2

Intercellular Adhesion Molecule 1 (CD54) Antibody

abx139532-01mg 0.1 mg
EUR 427.2

Intercellular Adhesion Molecule 1 (CD54) Antibody

abx021457-02mg 0.2 mg
EUR 560.4

Intercellular Adhesion Molecule 1 (CD54) Antibody

20-abx009132
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

ICAM-1(CD54) Mouse Monoclonal Antibody

Ab12144-100 100ul
EUR 578.4

VCAM-1(CD54) Mouse Monoclonal Antibody

Ab73313-050 50ul
EUR 562.8

VCAM-1(CD54) Mouse Monoclonal Antibody

Ab73313-100 100ul
EUR 724.8

Intercellular Adhesion Molecule 1 (CD54) Antibody

abx415026-02mg 0.2 mg
EUR 678

Intercellular Adhesion Molecule 1 (CD54) Antibody

abx415028-25ug 25 ug
EUR 326.4

Intercellular Adhesion Molecule 1 (CD54) Antibody

abx415520-02mg 0.2 mg
EUR 678

Intercellular Adhesion Molecule 1 (CD54) Antibody

abx415521-05mg 0.5 mg
EUR 994.8

Intercellular Adhesion Molecule 1 (CD54) Antibody

abx415524-01mg 0.1 mg
EUR 526.8

Intercellular Adhesion Molecule 1 (CD54) Antibody

abx412166-01mg 0.1 mg
EUR 844.8

Intercellular Adhesion Molecule 1 (CD54) Antibody

abx413013-05mg 0.5 mg
EUR 861.6

Intercellular Adhesion Molecule 1 (CD54) Antibody

abx413228-02mg 0.2 mg
EUR 678

Intercellular Adhesion Molecule 1 (CD54) Antibody

abx413229-05mg 0.5 mg
EUR 994.8

Intercellular Adhesion Molecule 1 (CD54) Antibody

abx413232-01mg 0.1 mg
EUR 526.8

Intercellular Adhesion Molecule 1 (CD54) Antibody

abx413235-20ug 20 ug
EUR 326.4

Anti-CD54 / ICAM-1 Monoclonal Antibody

M00171 100ug/vial
EUR 476.4
Description: Mouse Monoclonal CD54 / ICAM-1 Antibody. Validated in IHC and tested in Human.

Anti-ICAM1/Cd54 Rabbit Monoclonal Antibody

M00171-1 100ug/vial
EUR 476.4
Description: Rabbit Monoclonal ICAM1/Cd54 Antibody. Validated in IF, WB and tested in Human.

Goat ICAM-1/CD54 ELISA Kit

EGTI0332 96Tests
EUR 625.2

Bovine ICAM-1/CD54 ELISA Kit

EBI0332 96Tests
EUR 625.2

Canine ICAM-1/CD54 ELISA Kit

ECI0332 96Tests
EUR 625.2

sICAM-1/CD54 ELISA KIT|Human

EF002065 96 Tests
EUR 826.8

Anserini ICAM-1/CD54 ELISA Kit

EAI0332 96Tests
EUR 625.2

Recombinant Human ICAM-1/CD54 Protein

RP00272 5 μg
EUR 163.2

Recombinant Mouse ICAM-1/CD54 Protein

RP01056 5 μg
EUR 163.2

Recombinant Mouse ICAM-1/CD54 Protein

RP01065 10 μg
EUR 231.6

Mouse Anti Human Cd54 Monoclonal Antibody,FITC

CABT-46466MH 0.1 mg
EUR 795.6

Mouse Anti Human Cd54 Monoclonal Antibody,RPE

CABT-46472MH 100 TEST
EUR 852

Mouse Anti Rat Cd54 Monoclonal Antibody,RPE

CABT-46486MR 100 TEST
EUR 920.4

Rabbit Anti Human Cd54 Polyclonal Antibody,Biotin

CPBT-65043RH 50 µg
EUR 1057.2

CD54 (ICAM1) FITC Monoclonal Antibody (Clone 15.2)

6961-100
EUR 444

CD54 (ICAM1) FITC Monoclonal Antibody (Clone 15.2)

6961-25
EUR 235.2

Intercellular Adhesion Molecule 1 (CD54) Antibody (PE)

abx134368-100Assays 100 Assays
EUR 594

Intercellular Adhesion Molecule 1 (CD54) Antibody (PE)

abx134368-50Assays 50 Assays
EUR 477.6

Intercellular Adhesion Molecule 1 (CD54) Antibody (PE)

abx139533-100tests 100 tests
EUR 577.2

Intercellular Adhesion Molecule 1 (CD54) Antibody (PerCP)

abx139534-100tests 100 tests
EUR 577.2

Intercellular Adhesion Molecule 1 (CD54) Antibody (PE)

abx139535-100tests 100 tests
EUR 577.2

Intercellular Adhesion Molecule 1 (CD54) Antibody (APC)

abx139536-100tests 100 tests
EUR 577.2

Intercellular Adhesion Molecule 1 (CD54) Antibody (FITC)

abx415027-100tests 100 tests
EUR 610.8

Intercellular Adhesion Molecule 1 (CD54) Antibody (FITC)

abx415522-01mg 0.1 mg
EUR 610.8

Intercellular Adhesion Molecule 1 (CD54) Antibody (FITC)

abx415523-05mg 0.5 mg
EUR 861.6

Intercellular Adhesion Molecule 1 (CD54) Antibody (Biotin)

abx412167-50ug 50 ug
EUR 861.6

Intercellular Adhesion Molecule 1 (CD54) Antibody (FITC)

abx413230-01mg 0.1 mg
EUR 610.8
This case demonstrates for the primary time that an HCC affected person who’s proof against anti-PD-1 antibody immunotherapy can profit from anti-PD-L1 antibody immunotherapy, offering a probably promising technique for the therapy of HCC.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post